Hematological cancers are a major cause for the growing of mortality rate in patients worldwide. Myeloid and lymphoid malignancies are the main subtypes of blood cancers, and the distribution of them is different according to the geographical details. However, a considerable global population is affected by these cancers and it is essential to find some blood indicators specific for the subtypes of myeloid and lymphoid cancers. The availability of such blood markers helps to early diagnosis, treatment monitoring and grading of a cancer. Expression of some receptors on normal and diseased blood cells help the purpose as an indicator. Tyrosine protein kinase kit (C Kit) / Ligand-Stem Cell Factor (SCF) systems are responsible for the hematopoietic cell proliferation, cell survival and certain intracellular activities that takes place in the normal condition. C Kit receptor also shows a co expression with similar tyrosine kinase receptors which has same functions. In this review, we study the presence of C Kit (CD 117) on blood cells in hematological cancers to investigate the possibility of using C Kit/SCF systems for novel drug targets for them.

Keywords : C Kit System, SCF, Hematological Cancers, Blood Indicators.